AMLX · Insider Trading
Amylyx Pharmaceuticals, Inc. Common Stock
Every open-market purchase and sale reported by AMLX officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-10-07 | George M Milne Jr | Director | Sell | −30,000 | −$830.90K |
| 2026-09-14 | Camille L Bedrosian | Chief Medical Officer | Sell | −10,028 | −$324.87K |
| 2026-09-14 | Gina Mazzariello | Chief Legal Officer | Sell | −9,536 | −$309.51K |
| 2026-09-14 | Justin B. Klee | Co-Chief Executive Officer | Sell | −30,464 | −$980.26K |
| 2026-09-14 | Joshua B Cohen | Co-Chief Executive Officer | Sell | −30,464 | −$980.50K |
| 2026-09-14 | James M Frates | Chief Financial Officer | Sell | −10,810 | −$349.82K |
| 2026-09-02 | Karen Firestone | Director | M | +50,000 | +$170.25K |
| 2026-08-20 | Justin B. Klee | Co-Chief Executive Officer | A | +60,039 | — |
| 2026-08-20 | Camille L Bedrosian | Chief Medical Officer | A | +22,807 | — |
| 2026-08-20 | Joshua B Cohen | Co-Chief Executive Officer | A | +60,039 | — |
| 2026-08-20 | Gina Mazzariello | Chief Legal Officer | A | +21,284 | — |
| 2026-08-20 | James M Frates | Chief Financial Officer | A | +22,807 | — |
| 2026-07-13 | Gina Mazzariello | Chief Legal Officer | Sell | −30,000 | −$538.87K |
| 2026-06-08 | George M Milne Jr | Director | A | +24,372 deriv. | — |
| 2026-06-08 | Bernhardt G Zeiher | Director | A | +24,372 deriv. | — |
| 2026-06-08 | Karen Firestone | Director | A | +24,372 deriv. | — |
| 2026-06-08 | Paul R. Fonteyne | Director | A | +24,372 deriv. | — |
| 2026-06-08 | Daphne Quimi | Director | A | +24,372 deriv. | — |
| 2026-05-26 | Karen Firestone | Director | Buy | +3,800 | +$51.34K |
| 2026-03-09 | Justin B. Klee | Co-Chief Executive Officer | A | +248,865 | — |
| 2026-03-09 | Camille L Bedrosian | Chief Medical Officer | A | +95,990 | — |
| 2026-03-09 | Gina Mazzariello | Chief Legal Officer | A | +74,660 | — |
| 2026-03-09 | Joshua B Cohen | Co-Chief Executive Officer | A | +248,865 | — |
| 2026-03-09 | James M Frates | Chief Financial Officer | A | +95,990 | — |
| 2026-03-04 | Camille L Bedrosian | Chief Medical Officer | Sell | −6,461 | −$94.21K |
| 2026-03-04 | James M Frates | Chief Financial Officer | Sell | −7,909 | −$114.85K |
| 2026-03-04 | Joshua B Cohen | Co-Chief Executive Officer | Sell | −29,282 | −$424.12K |
| 2026-03-04 | Gina Mazzariello | Chief Legal Officer | Sell | −6,844 | −$99.38K |
| 2026-03-04 | Justin B. Klee | Co-Chief Executive Officer | Sell | −29,282 | −$423.76K |
| 2026-02-25 | Gina Mazzariello | Chief Legal Officer | Sell | −3,419 | −$48.35K |
| 2026-02-04 | Joshua B Cohen | Co-Chief Executive Officer | Sell | −15,500 | −$227.59K |
| 2026-02-04 | Justin B. Klee | Co-Chief Executive Officer | Sell | −15,500 | −$227.62K |
| 2026-02-04 | Gina Mazzariello | Chief Legal Officer | Sell | −3,448 | −$50.52K |
| 2026-02-04 | James M Frates | Chief Financial Officer | Sell | −3,557 | −$52.10K |
| 2026-01-20 | Joshua B Cohen | Co-Chief Executive Officer | MIXED | +61,833 | −$364.09K |
| 2026-01-20 | Justin B. Klee | Co-Chief Executive Officer | MIXED | +61,812 | −$363.57K |
| 2026-01-14 | George M Milne Jr | Director | G | −17,780 | — |
| 2026-01-08 | Joshua B Cohen | Co-Chief Executive Officer | Sell | −7,715 | −$85.60K |
| 2026-01-08 | James M Frates | Chief Financial Officer | Sell | −3,326 | −$36.95K |
| 2026-01-08 | Justin B. Klee | Co-Chief Executive Officer | Sell | −7,715 | −$85.59K |
| 2025-12-23 | Karen Firestone | Director | Buy | +8,100 | +$100.84K |
| 2025-12-03 | Camille L Bedrosian | Chief Medical Officer | Sell | −6,580 | −$94.42K |
| 2025-10-02 | Camille L Bedrosian | Chief Medical Officer | Sell | −12,039 | −$175.52K |
| 2025-10-02 | Justin B. Klee | Co-Chief Executive Officer | Sell | −29,975 | −$430.95K |
| 2025-10-02 | Gina Mazzariello | Chief Legal Officer | Sell | −8,828 | −$128.67K |
| 2025-10-02 | Joshua B Cohen | Co-Chief Executive Officer | Sell | −29,933 | −$429.47K |
| 2025-10-02 | James M Frates | Chief Financial Officer | Sell | −10,558 | −$154.65K |
| 2025-08-14 | Gina Mazzariello | Chief Legal Officer | Sell | −30,000 | −$246.15K |
| 2025-06-09 | Paul R. Fonteyne | Director | A | +25,000 deriv. | — |
| 2025-06-09 | George M Milne Jr | Director | A | +25,000 deriv. | — |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Joshua B Cohen | Co-Chief Executive Officer | 3,614,042 | $97.90M |
| Justin B. Klee | Co-Chief Executive Officer | 3,613,056 | $97.88M |
| George M Milne Jr | Director | 782,881 | $21.21M |
| James M Frates | Chief Financial Officer | 333,625 | $9.04M |
| Camille L Bedrosian | Chief Medical Officer | 278,064 | $7.53M |
| Gina Mazzariello | Chief Legal Officer | 190,849 | $5.17M |
| Karen Firestone | Director | 91,900 | $2.49M |
| Bernhardt G Zeiher | Director | 10,000 | $270.90K |
| Paul R. Fonteyne | Director | 3,947 | $106.92K |
| Daphne Quimi | Director | 2,750 | $74.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the AMLX quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.